Лекарства GLP-1, подобные Оземпику, могут помочь снизить тяжесть симптомов мигрени.

on PinterestRecent research has found that GLP-1s may reduce the need for emergency care in those with chronic migraine.

on PinterestRecent research has found that GLP-1s may reduce the need for emergency care in those with chronic migraine. Image Credit: Maskot/Getty Images

• A recent study suggests that GLP-1 drugs, like Ozempic, may make people with chronic migraine less likely to require emergency care.
• People using GLP-1s may be less likely to need new preventive migraine medications.
• The study does not prove that GLP-1s lower emergency care needs for people with chronic migraine, but it shows an association.
• More research is needed to determine how GLP-1s could help in the future of migraine management.

Migraine is a common condition both worldwide and throughout the United States. It may affect females more than males, but anyone can experience migraine.

According to the American Migraine Foundation, 148 million people worldwide live with migraine.

This condition affects 37 million people in the United States. It is the third most common disease in the world and one of the 10 most disabling conditions.

Of those who experience migraine, 2% experience chronic migraine. Migraine is considered chronic when a person experiences 15 or more days per month with a headache for more than 3 months. Of these, at least 8 days per month have other features of migraine, such as aura, nausea, and heightened sensitivity to light and sound.

A recent preliminary study by researchers in Brazil and the United States suggests that GLP-1 medications for weight loss, such as Ozempic and Wegovy, may reduce the need for emergency care among people with chronic migraine compared with those who are treated with topiramate for migraine prevention.

This study has not yet been published in a peer-reviewed scientific journal. It will be presented at the American Academy of Neurology Annual Meeting, April 18–22, 2026, being held in Chicago and online.

“People with chronic migraine often end up in the emergency room, or they need to try several preventive medications before finding one that can work for them,” study author Vitoria Acar, MD, of the Brazil, and one of the study authors, said in a press release.

“Seeing these patterns of lower use of emergency care and lower use of drugs to stop migraines or trying additional drugs to prevent migraines among people taking GLP-1 drugs for other conditions suggests that these therapies may help stabilize the disease burden in ways that we haven’t fully appreciated yet,” Acar said.

GLP-1s lower ER visits for chronic migraine by 10%

For this study, the researchers analyzed data from a health record database of people with chronic migraine based on medical records.

They compared people who had begun taking a GLP-1 medication for other reasons, like weight loss, within a year of receiving a diagnosis of chronic migraine to individuals who started taking topiramate during the same period.

Each group consisted of around 11,000 people. The two groups were matched for factors such as:

• age
• body mass index (BMI)
• other health conditions
• prior migraine treatments

The GLP-1 medications included in the study were:

• liraglutide (Saxenda, Victoza)
• semaglutide (Ozempic, Wegovy)
• dulaglutide (Trulicity)
• exenatide (Byetta, Bydureon)
• lixisenatide (Adlyxin)
• albiglutide (Tanzeum, Eperzan)

The researchers

Узнайте больше о пересадка волос в клинике Rubenhair.